MX2015007940A - Compuestos tricíclicos como inhibidores de cftr. - Google Patents
Compuestos tricíclicos como inhibidores de cftr.Info
- Publication number
- MX2015007940A MX2015007940A MX2015007940A MX2015007940A MX2015007940A MX 2015007940 A MX2015007940 A MX 2015007940A MX 2015007940 A MX2015007940 A MX 2015007940A MX 2015007940 A MX2015007940 A MX 2015007940A MX 2015007940 A MX2015007940 A MX 2015007940A
- Authority
- MX
- Mexico
- Prior art keywords
- tricyclic compounds
- cftr inhibitors
- present
- cftr
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto de la fórmula I o una sal farmacéuticamente aceptable del mismo; (ver fórmula) y sus usos terapéuticos. La presente invención proporciona además una combinación de los agentes farmacológicamente activos y una composición farmacéutica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261739337P | 2012-12-19 | 2012-12-19 | |
US201361906154P | 2013-11-19 | 2013-11-19 | |
PCT/IB2013/061041 WO2014097147A1 (en) | 2012-12-19 | 2013-12-17 | Tricyclic compounds as cftr inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015007940A true MX2015007940A (es) | 2016-03-11 |
Family
ID=50030371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015007940A MX2015007940A (es) | 2012-12-19 | 2013-12-17 | Compuestos tricíclicos como inhibidores de cftr. |
Country Status (15)
Country | Link |
---|---|
US (1) | US9303035B2 (es) |
EP (1) | EP2935277B1 (es) |
JP (1) | JP6284545B2 (es) |
KR (1) | KR20150095925A (es) |
CN (1) | CN105008370B (es) |
AR (1) | AR094123A1 (es) |
AU (1) | AU2013365827A1 (es) |
BR (1) | BR112015014433A2 (es) |
CA (1) | CA2895656A1 (es) |
EA (1) | EA201591175A1 (es) |
ES (1) | ES2650372T3 (es) |
MX (1) | MX2015007940A (es) |
TW (1) | TW201429976A (es) |
UY (1) | UY35209A (es) |
WO (1) | WO2014097147A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
MX2015007940A (es) | 2012-12-19 | 2016-03-11 | Novartis Ag | Compuestos tricíclicos como inhibidores de cftr. |
AP2015008539A0 (en) * | 2012-12-19 | 2015-06-30 | Novartis Ag | Tricyclic compounds for inhibiting the CFTR channel |
KR20180101416A (ko) * | 2015-12-24 | 2018-09-12 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Cftr 조절제 및 이의 이용 방법 |
KR20200044873A (ko) | 2017-08-24 | 2020-04-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구 제약학적 조성물 |
CN112724157B (zh) * | 2021-01-23 | 2022-04-19 | 中国科学院新疆理化技术研究所 | 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途 |
KR20240004584A (ko) | 2021-04-29 | 2024-01-11 | 노파르티스 아게 | 탈유비퀴티나아제-표적화 키메라 및 관련된 방법 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW224974B (es) * | 1991-07-02 | 1994-06-11 | Hoffmann La Roche | |
US6608098B1 (en) | 1999-08-25 | 2003-08-19 | Banyu Pharmaceutical Co., Ltd. | Isoindole derivatives |
JP2002255967A (ja) | 2001-02-27 | 2002-09-11 | Banyu Pharmaceut Co Ltd | イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。 |
EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
KR20090087487A (ko) | 2006-12-12 | 2009-08-17 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
WO2009042270A2 (en) * | 2007-07-05 | 2009-04-02 | Trustees Of Boston University | Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
CA2769847C (en) * | 2009-08-10 | 2019-01-08 | The Regents Of The University Of California | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
WO2012166658A1 (en) * | 2011-05-27 | 2012-12-06 | The Regents Of The University Of California | Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor |
MX2015007940A (es) | 2012-12-19 | 2016-03-11 | Novartis Ag | Compuestos tricíclicos como inhibidores de cftr. |
AP2015008539A0 (en) * | 2012-12-19 | 2015-06-30 | Novartis Ag | Tricyclic compounds for inhibiting the CFTR channel |
-
2013
- 2013-12-17 MX MX2015007940A patent/MX2015007940A/es unknown
- 2013-12-17 CN CN201380073219.8A patent/CN105008370B/zh active Active
- 2013-12-17 WO PCT/IB2013/061041 patent/WO2014097147A1/en active Application Filing
- 2013-12-17 AU AU2013365827A patent/AU2013365827A1/en not_active Abandoned
- 2013-12-17 JP JP2015548836A patent/JP6284545B2/ja active Active
- 2013-12-17 EP EP13826624.2A patent/EP2935277B1/en active Active
- 2013-12-17 KR KR1020157019356A patent/KR20150095925A/ko not_active Application Discontinuation
- 2013-12-17 US US14/109,927 patent/US9303035B2/en active Active
- 2013-12-17 CA CA2895656A patent/CA2895656A1/en not_active Abandoned
- 2013-12-17 BR BR112015014433A patent/BR112015014433A2/pt not_active IP Right Cessation
- 2013-12-17 EA EA201591175A patent/EA201591175A1/ru unknown
- 2013-12-17 ES ES13826624T patent/ES2650372T3/es active Active
- 2013-12-18 TW TW102147022A patent/TW201429976A/zh unknown
- 2013-12-19 UY UY0001035209A patent/UY35209A/es not_active Application Discontinuation
- 2013-12-19 AR ARP130104862A patent/AR094123A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2935277B1 (en) | 2017-08-30 |
AR094123A1 (es) | 2015-07-08 |
KR20150095925A (ko) | 2015-08-21 |
AU2013365827A1 (en) | 2015-07-09 |
CN105008370B (zh) | 2017-06-09 |
EA201591175A1 (ru) | 2015-11-30 |
WO2014097147A1 (en) | 2014-06-26 |
UY35209A (es) | 2014-07-31 |
EP2935277A1 (en) | 2015-10-28 |
US20140171412A1 (en) | 2014-06-19 |
TW201429976A (zh) | 2014-08-01 |
CA2895656A1 (en) | 2014-06-26 |
BR112015014433A2 (pt) | 2017-07-11 |
ES2650372T3 (es) | 2018-01-18 |
CN105008370A (zh) | 2015-10-28 |
JP6284545B2 (ja) | 2018-02-28 |
JP2016507498A (ja) | 2016-03-10 |
US9303035B2 (en) | 2016-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
PH12016500072A1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
MX2019010446A (es) | Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4. | |
MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
IN2015DN00185A (es) | ||
MX2020011652A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
MX2016000675A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos. | |
MX2015007940A (es) | Compuestos tricíclicos como inhibidores de cftr. | |
MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
IN2014DN10670A (es) | ||
PH12014502462A1 (en) | Complement pathway modulators and uses thereof | |
GB201209587D0 (en) | Therapeutic compounds | |
MX340574B (es) | Imidazo pirazinas. | |
PH12015501386A1 (en) | Tricyclic compounds | |
TN2014000060A1 (en) | Benzothiazolone compound | |
MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
MX2016013561A (es) | Activadores de herg policiclicos. | |
TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors |